Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Inclusion Criteria:

• Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2 (randomisation)

• Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidaseinhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeksprior to Visit 2 (randomisation) and doses should have been stable in this period oftime

• Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratoryanalysis

• Body mass index (BMI) below or equal to 40 kg/m^2

Exclusion Criteria:

• Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones (TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)

• Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardialinfarction; unstable angina pectoris; or coronary arterial bypass graft orangioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)

• Uncontrolled or untreated severe hypertension defined as systolic blood pressure aboveor equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg

• Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12months) or hypoglycaemic unawareness as judged by the investigator

• Life-threatening disease (e.g. cancer)